Moderna’s Cancer-Vaccine Leak Spurred Panic Selling as Wall Street Wanted a Cure

Moderna and Merck’s cancer vaccine reduced the risk of melanoma recurrence or death by 42%, but investors questioned its potential across other cancers.

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.barrons.com)